Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Zentalis Pharmaceuticals Q3 EPS $(0.96) Down From $(0.09) YoY

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported quarterly losses of $(0.96) per share. This is a 966.67 percent decrease over losses of $(0.09) per share from the same period last year.
byBenzinga Newsdesk
November 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported quarterly losses of $(0.96) per share. This is a 966.67 percent decrease over losses of $(0.09) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Allergan Aesthetics Announces Topline Results From Second Phase 3 Study Of OnabotulinumtoxinA (Botox Cosmetic) For The Treatment Of Platysma Prominence; All Primary And Secondary Endpoints Were Met

By Benzinga Newsdesk
September 18, 9:01 AM
–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).–Results support onabotulinumtoxinA as a potential treatment

ABBV